Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [11] Skin Autofluorescence Is Associated with Tubular Injury Represented by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Diabetes
    Yamagami, Hiroki
    Yasui, Saya
    Hosoki, Minae
    Hori, Taiki
    Hara, Tomoyo
    Mitsui, Yukari
    Kurahashi, Kiyoe
    Nakamura, Shingen
    Otoda, Toshiki
    Yuasa, Tomoyuki
    Yoshida, Sumiko
    Kuroda, Akio
    Matsuhisa, Munehide
    Endo, Itsuro
    Aihara, Ken-Ichi
    Abe, Masahiro
    DIABETES, 2022, 71
  • [12] Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis
    Mou, Shan
    Wang, Qin
    Li, Jialin
    Shi, Beili
    Ni, Zhaohui
    CLINICA CHIMICA ACTA, 2012, 413 (1-2) : 187 - 191
  • [13] Clinical usefulness of urinary liver-type fatty acid-binding protein in congenital anomalies of the kidney and urinary tract
    Tanaka, Ryojiro
    Nakagawa, Taku
    Kanda, Kyoko
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1402 - 1402
  • [14] PROGNOSTIC VALUE OF URINARY CONCENTRATION OF LIVER-TYPE FATTY ACID-BINDING PROTEIN IN CHRONIC KIDNEY DISEASE
    Kanayama, Kyoko
    Hasegawa, Midori
    Kitagawa, Fumihiko
    Ishii, Jyunichi
    Yuzawa, Yukio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 109 - 110
  • [15] Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules
    Kamijo, A
    Sugaya, T
    Hikawa, S
    Okada, M
    Okumura, F
    Yamanouchi, M
    Honda, A
    Okabe, M
    Fujino, T
    Hirata, Y
    Omata, M
    Kaneko, R
    Fujii, H
    Fukamizu, A
    Kimura, K
    AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (04): : 1243 - 1255
  • [16] Urinary liver-type fatty acid-binding protein: A hemodynamic index during extracorporeal membrane oxygenation
    Ichibayashi, Ryo
    Yamamoto, Saki
    Nakamichi, Yoshimi
    Masuyama, Yuka
    Serizawa, Hibiki
    Watanabe, Masayuki
    Yabe, Takayuki
    Honda, Mitsuru
    CLINICAL CASE REPORTS, 2022, 10 (11):
  • [17] Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy
    Nakamura, Tsukasa
    Fujiwara, Nobuharu
    Sugaya, Takeshi
    Ueda, Yoshihiko
    Koide, Hikaru
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (08): : 1185 - 1190
  • [18] Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients
    Nielsen, Stine Elkjaer
    Sugaya, Takeshi
    Hovind, Peter
    Baba, Tsuneharu
    Parving, Hans-Henrik
    Rossing, Peter
    DIABETES CARE, 2010, 33 (06) : 1320 - 1324
  • [19] Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Kawagoe, Yasuhiro
    Ueda, Yoshihiko
    Koide, Hikaru
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2006, 22 (05) : 385 - 389
  • [20] Urinary liver-type fatty acid-binding protein as a prognostic marker in patients with acute heart failure
    Sunayama, Tsutomu
    Yatsu, Shoichiro
    Matsue, Yuya
    Dotare, Taishi
    Maeda, Daichi
    Ishiwata, Sayaki
    Nakamura, Yutaka
    Suda, Shoko
    Kato, Takao
    Hiki, Masaru
    Kasai, Takatoshi
    Minamino, Tohru
    ESC HEART FAILURE, 2022, 9 (01): : 442 - 449